IL4 injections into mice engrafted with AML cells resulted in lower leukemia burden in both blood (Figure 6a) and bone marrow (Figure 6b), accompanied by a significantly prolonged survival (median 26 versus 23 days, P<0.01; Figure 6c). Here, IL4 is linked to acute myeloid leukemia.